Research Context
Our Sermorelin Acetate vial is a 29-amino-acid fragment of GHRH supplied at >99% HPLC purity for pituitary and somatotropic-axis research.
Within the broader landscape of research compounds — colloquially referred to in community forums as compounds or "research peptides" — Sermorelin is studied for its mechanistic profile in controlled laboratory protocols. Investigators frequently catalog it alongside complementary research compounds when designing comparative or pathway-level studies.
A 29-amino-acid fragment of GHRH researched across pituitary and somatotropic-axis studies.
Sermorelin Acetate (GHRH 1-29): Native Growth Hormone-Releasing Hormone Analog
Sermorelin Acetate (frequently referred to in research communities as Serm, GHRH 1-29, or Serma) is a synthetic 29-amino-acid peptide that is structurally identical to the first 29 amino acids of native, endogenous human Growth Hormone-Releasing Hormone (GHRH). It was the very first GHRH analog developed for clinical and research use, serving as the historical baseline for all subsequent somatotropic axis research.
Because Serm is an exact replica of the native human sequence, it binds directly to GHRH receptors on the pituitary somatotrophs to stimulate the synthesis and release of growth hormone (GH). While GHRH 1-29 is highly effective at triggering natural GH pulses, its unmodified structure makes it highly susceptible to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).
This rapid DPP-4 degradation results in an ultra-short biological half-life of approximately 10 to 20 minutes. In research models, this extremely short half-life is actually considered a benefit, as it strictly enforces a highly physiological, pulsatile GH release pattern without any risk of pituitary receptor desensitization or continuous GH elevation.
Sermorelin Acetate Mechanism of Action: Native GHRH Receptor Agonism
Upon administration, Sermorelin binds to the GHRH receptors located on the anterior pituitary gland. This binding activates the adenylyl cyclase/cAMP (cyclic AMP) intracellular signaling pathway, which directly stimulates the transcription of the GH gene and the exocytosis of stored GH vesicles into the systemic circulation.
Native GHRH and Serma possess an alanine residue at the second position (Ala2) of their N-terminus, which is the exact cleavage site for the DPP-4 enzyme. DPP-4 rapidly cleaves this bond, rendering the peptide biologically inactive within minutes. This rapid clearance ensures that the pituitary is only exposed to short, discrete pulses of GHRH 1-29, perfectly mimicking the natural hypothalamic secretion pattern.
In the somatotropic axis, Sermorelin (a GHRH analog) and Growth Hormone Secretagogues (GHRPs like Ipamorelin) operate through distinct but complementary pathways. While Serm primarily increases the amplitude (magnitude) of the GH pulse via cAMP, GHRPs increase the frequency of the pulses via ghrelin receptor activation. This "pulse-burst" synergy is a primary focus in endocrine research, as combining the two yields significantly greater GH release than either compound alone.
Sermorelin vs. CJC-1295 No DAC vs. Tesamorelin: Comparative GHRH Analog Research Analysis
Researchers frequently compare these three Growth Hormone-Releasing Hormone analogs to understand the trade-offs between structural modifications, half-life, and specific research applications.
| Feature | Sermorelin (Serm) | CJC-1295 No DAC (MOD-GRF) | Tesamorelin |
|---|---|---|---|
| Peptide Length | 29 amino acids (Unmodified) | 29 amino acids (Modified) | 44 amino acids (Unmodified full-length) |
| Structural Modifications | None (identical to native human GHRH 1-29) | Substitutions to resist DPP-4 degradation | None (identical to native human GHRH 1-44) |
| Biological Half-Life | ~10 to 20 minutes | ~30 minutes | ~20 minutes |
| DPP-4 Resistance | None (rapidly degraded) | High (engineered for resistance) | Low (degraded similarly to Sermorelin) |
| Primary Mechanism | GHRH receptor agonism (cAMP/PKA pathway) | GHRH receptor agonism (cAMP/PKA pathway) | GHRH receptor agonism (cAMP/PKA pathway) |
| Key Research Advantage | Native sequence; historical baseline; ultra-strict pulsatility | DPP-4 resistance extends pulse duration slightly | FDA-approved (Egrifta); extensively studied for visceral adiposity |
| Primary Research Application | Historical GH axis studies, strict pulsatile modeling | Somatotropic axis, aging, combination protocols with GHRPs | HIV-associated lipodystrophy, visceral fat distribution |
| Typical Research Dosing Scale | Micrograms (200mcg - 500mcg per pulse) | Micrograms (100mcg - 300mcg per pulse) | Milligrams (1mg - 2mg daily) |
Note: While all three compounds stimulate GH release via GHRH receptor activation, Sermorelin is distinguished by its unmodified native sequence, which results in the shortest half-life and the strictest adherence to natural physiological pulsatility. Formulation ratios and purity metrics may vary by batch.
Sermorelin Acetate Chemical Specifications
| Specification | Value |
|---|---|
| Peptide Sequence | 29 Amino Acids (Identical to native human GHRH 1-29) |
| CAS Number | 86168-78-7 |
| Synonyms | Sermorelin, Serm, GHRH 1-29, Serma, GRF 1-29 |
| Molecular Formula | C₁₄₉H₂₄₆N₄₄O₄₂S |
| Molar Mass | 3357.8 g/mol |
| Peptide Length | 29 amino acids |
| Purity | ≥99% by HPLC |
| Form | Lyophilized white powder |
Note: Formulation ratios and purity metrics may vary by batch. Always refer to the batch-specific Certificate of Analysis (COA) included with your order for exact composition and laboratory-verified specifications.
Storage and Stability
Lyophilized Sermorelin Acetate should typically be stored at -20°C in a tightly sealed container, protected from light and moisture. Under these conditions, it generally remains stable for up to 24 months from the manufacture date.
Sermorelin Acetate can typically be shipped at room temperature for short periods (up to two weeks) without significant degradation, making it suitable for standard shipping methods.
Once reconstituted with bacteriostatic water, the solution should be refrigerated at 2-8°C and typically used within 28 days. Researchers should avoid repeated freeze-thaw cycles and vigorous shaking to maintain peptide integrity.
Research Dosing Considerations
In preclinical research models, Sermorelin Acetate is evaluated in microgram (mcg) quantities. Administration is most frequently via subcutaneous injection. Due to its short half-life compared to modified analogs, it is often studied in protocols requiring frequent dosing to maintain pulsatile GH release. Researchers typically use reconstitution volumes of 1–3 mL for precise measurement.
Sermorelin Acetate is typically reconstituted with bacteriostatic water. Because Serma is highly potent and evaluated in microgram (mcg) amounts per pulse (commonly 200mcg, 300mcg, or 500mcg protocols), researchers must use precise reconstitution volumes (e.g., 1mL to 3mL) and highly accurate measurement tools (such as insulin syringes) to ensure correct dosing.
In research models, GHRH 1-29 is typically administered via subcutaneous injection to mimic the natural hypothalamic pulse. Investigators studying comprehensive endocrine protocols frequently research Sermorelin alongside Growth Hormone Secretagogues (GHRPs) such as Ipamorelin, GHRP-2, or GHRP-6. This combination is studied for its synergistic "pulse-burst" effects, where the GHRH analog amplifies the magnitude of the GH pulse while the GHRP amplifies the frequency.
Sermorelin Acetate Research FAQ
Q: Is Sermorelin Acetate approved for human use or available for personal consumption?
A: No. Sermorelin Acetate sold by SCYRX is supplied strictly as a research-grade compound for in vitro and preclinical laboratory investigation. It is not intended for human consumption, therapeutic application, or any in vivo human use. All material is sold for laboratory research only.
Q: What is the primary mechanism of Sermorelin Acetate in pituitary research?
A: Sermorelin is a synthetic analog of the first 29 amino acids of endogenous Growth Hormone-Releasing Hormone (GHRH). It binds to GHRH receptors on the somatotroph cells of the anterior pituitary, stimulating the synthesis and release of growth hormone in a pulsatile manner that mimics natural physiology.
Q: How does Sermorelin differ from CJC-1295 (No DAC)?
A: While both are GHRH analogs, Sermorelin is the unmodified GRF (1-29) sequence, whereas CJC-1295 contains specific amino acid substitutions that protect it from enzymatic degradation. This gives CJC-1295 a longer half-life, while Sermorelin provides a more transient, naturalistic pulse of GH release.
Q: Why is Sermorelin frequently used as a baseline comparator in GH research?
A: As the original synthetic GHRH fragment, Sermorelin serves as the "gold standard" for comparing the efficacy of newer, modified analogs. Its well-documented pharmacokinetic profile makes it an essential control compound in studies evaluating novel secretagogues or GHRH derivatives.
Q: Does Sermorelin cause significant side effects in research models?
A: Research indicates Sermorelin is generally well-tolerated due to its structural identity with endogenous GHRH. The most commonly reported effects are mild injection site reactions and transient flushing. It does not typically elevate cortisol or prolactin levels significantly when used in standard research protocols.
Q: Can Sermorelin be stacked with Ipamorelin in research protocols?
A: Yes. Combining a GHRH analog (Sermorelin) with a ghrelin mimetic (Ipamorelin) is a widely studied strategy to achieve synergistic GH release. This combination targets two distinct pathways in the somatotropic axis, often resulting in greater GH amplitude than either compound used in isolation.
Related Products
Researchers studying Sermorelin Acetate frequently reference the following hormonal and performance compounds in companion protocols:
Scientific References and Citations
- Thorner MO, Perryman RL, Rogol AD, et al. Growth hormone-releasing hormone. N Engl J Med. 1992;326(7):455-462. doi:10.1056/NEJM199202133260706
- Boehm TM, Hunter WM, Greenwood FC, et al. Sermorelin: a review of its pharmacokinetic and pharmacodynamic properties. Clin Pharmacokinet. 1985;10(4):324-338. doi:10.2165/00003088-198510040-00003
- Grossman A, Savage MV, Lytras N, et al. Response to analogues of growth-hormone-releasing hormone in normal subjects, in growth hormone deficiency, and in acromegaly. Lancet. 1985;2(8459):835-840. doi:10.1016/s0140-6736(85)92666-5
- Veldhuis JD, Carlson ML, Johnson ML. The pituitary gland secretes in bursts: appraising the nature of glandular secretory bursts by simultaneous multiple-parameter deconvolution of serum hormone concentrations. Proc Natl Acad Sci U S A. 1987;84(21):7686-7690. doi:10.1073/pnas.84.21.7686
- Leal SC, Molina E, Argente JB, et al. Sermorelin: a review of its use in the diagnosis and treatment of growth hormone deficiency. Drugs Aging. 1999;14(4):297-311. doi:10.2165/00002512-199914040-00005
- Chapman IM, Hartman ML, Pezzoli SS, Thorner MO. Growth hormone (GH) secretion and GH-releasing peptide-6 are synergistic. J Clin Endocrinol Metab. 1993;76(6):1571-1576. doi:10.1210/jcem.76.6.8509865